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INTRODUCTION
Nodular thyroid disease is a very common disorder. Accord-
ing to the Framingham database (1), the estimated lifetime
risk of having a thyroid nodule is 5-10%. However, thyroid
cancer represents just 1-2% of all malignancies and only 5-
24% of thyroid nodules treated surgically are malignant.
These days, fine-needle aspiration (FNA) is the best tool for
the evaluation of thyroid nodules. But misdiagnoses may
occur, due to either insufficient or unsuitable aspirated mate-
rial or sampling error. Furthermore, the main limitation of
FNA is the lack of sensitivity in the evaluation of follicular
neoplasms, due to the inability to differentiate follicular ade-
noma from carcinoma. If a more reliable marker for the pres-
ence of thyroid cancer were available for preoperative evalu-
ation, we could avoid unnecessary thyroid surgeries.
Invasion and metastasis are one of the main characteristics
of cancer. They are a complex process that includes changes
in cell adhesion, allowing transformed cells to invade and
migrate through the extracellular matrix (ECM) (2). Focal
adhesions are considered to be a key role in this change (3).
Focal adhesions are cell-ECM contact points containing mem-
brane-associated, cytoskeletal, and intracellular signaling
molecules. A number of proteins are found to be preferentially
associated with the focal adhesion complex, including focal
adhesion kinase (FAK), paxillin, vinculin, and talin. Among
these proteins, FAK is a critical mediator of signaling events
between cells and the ECM (4). FAK is a cytosolic protein of
125 kDa, first recognized as a major phosphotyrosine-contain-
ing protein in v-Src-transformed chicken embryo fibroblasts
(5). FAK is associated with the cytoplasmic domain of integrin
receptors, and becomes phosphorylated in response to integrin-
mediated cell adhesion, integrin clustering, cell migration
(6, 7), stimulation by mitogenic neuropeptides such as bom-
besin (8), and transformation by v-Src, v-Crk and Bcr-Abl (9).
This, in turn, allows for the association of mitogenic proteins
that contribute to the control of cell growth and differentiation.
The potential involvement of FAK in promotion of cell pro-
liferation and migration in several cell types in vitro suggests
that FAK could potentially play a role in neoplastic processes
in which cell proliferation has escaped control mechanisms. 
Evidence suggests that FAK is overexpressed in various
tumors, including tumors derived from regions of the head
and neck, colon, breast, prostate, liver, cervix, and thyroid (10-
19). In this study, we investigated FAK expression in thyroid
cancers and the possibility of its usage as a tumor marker.
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Increased Expression of Focal Adhesion Kinase in Thyroid Cancer:
Immunohistochemical Study
Focal adhesion kinase (FAK) is a tyrosine kinase that is found in cellular structures
called focal adhesions. FAK appears to be a key element in signal transduction path-
ways involved in cell adhesion and locomotion. FAK is overexpressed in various
tumors, including tumors derived from regions of the head and neck, colon, breast,
prostate, and liver. In this study, we investigated immunohistochemically whether
FAK expression was increased in thyroid cancers. FAK staining was not seen in any
of the 20 normal thyroid tissues or the 6 nodular hyperplasia specimens. In contrast,
FAK staining was observed in all of 17 papillary carcinomas, 9 follicular carcinomas,
8 medullary carcinomas, and 2 anaplastic carcinomas. Nine of 17 follicular adeno-
mas showed FAK immunoreactivity. FAK was not expressed in normal tissue and
nodular hyperplasia, but was expressed in some of the follicular adenoma, and all
of the follicular, papillary, medullary and anaplastic thyroid carcinoma. This result
indicates that the up-regulation of FAK may play a role in the development of thy-
roid carcinogenesis. 
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MATERIALS AND METHODS
Specimens
Fifty-nine paraffin-embedded thyroid specimens were ob-
tained from surgical resections performed due to thyroid nod-
ules. These consisted of 17 papillary carcinomas, 9 follicular
carcinomas, 17 follicular adenomas, 6 nodular hyperplasias,
8 medullary thyroid carcinomas (MTC), and 2 anaplastic car-
cinomas. Twenty normal thyroid tissues were used as controls.
Normal tissue samples were taken from histologically normal
areas adjacent to the neoplastic lesion.
Immunohistochemistry
Immunohistochemical analysis of FAK was performed using
established protocols. Briefly, paraffin-embedded tissue was
cut into 5  m section and dried for 1 hr at 57℃in oven. After
routine deparaffinization and rehydration, tissue sections were
microwaved for 20 min in 0.01 M sodium citrate buffer (pH
6.0). Endogenous peroxidase activity was blocked with 3%
H2O2 in methanol for 30 min followed by incubation with
rabbit antihuman FAK antibody (Upstate Biotechnology,
Lake Placid, NY, U.S.A.) at a dilution of 1:100 for 60 min
at room temperature. Then, all slides were washed 3 times for
3 min each with phosphate-buffered saline (PBS). Samples
were incubated with PicTure-plus bulk kit (Zymed Lab, San
Francisco, CA, U.S.A.), that is Zymed’s HRP polymer detec-
tion system, for 20 min at room temperature, washed and
incubated with Liquid DAB substrate kit (Zymed Lab) for
5 min. And then counterstained with Mayer’s hematoxylin
for 5 min and mo- unted. For negative controls, incubation
with the primary antibody was omitted. Staining was scored
as follows: 0 (-)= absent, 1 (+)=weak staining, 2 (++)=mod-
erate staining, and 3 (+++)=strong staining in epithelial cells.
Statistical analysis
The correlation between the total score of FAK expression
Tumor type (No. of cases) - + ++ +++
Papillary carcinoma (17) 0 3 4 10
Follicular carcinoma (9) 0 1 4 4
Medullary carcinoma (8) 0 0 0 8
Anaplastic carcinoma (2) 0 0 1 1
Follicular adenoma (17) 8 4 2 3
Nodular hyperplasia (6) 6 0 0 0
Normal tissue (20) 20 0 0 0
Table 1. Expression of FAK in thyroid lesions
+++, strong staining; ++, moderate staining; +, weak staining; -, no
staining.
Patient Tumor type Sex/Age (yr) Tumor size (cm) Metastasis or invasion Staining intensity
1 Papillary carcinoma F/29 2.5×1.5 LN +++ 
2 Papillary carcinoma M/38 3.5×2 LN ++ 
3 Papillary carcinoma M/65 1.3×1 LN +++ 
4 Papillary carcinoma F/48 5×4.5 LN +++ 
5 Papillary carcinoma F/47 3×2L N +  
6 Papillary carcinoma M/68 3×3 LN +++ 
7 Papillary carcinoma F/35 1.7×1.2 LN & soft tissue invasion +++
8 Papillary carcinoma F/72 4.5×4 Soft tissue invasion +++
9 Papillary carcinoma F/52 3×3+ +
10 Papillary carcinoma F/57 5×4+
11 Papillary carcinoma F/27 3.5×3.5 +++
12 Papillary carcinoma F/33 4×3 +++
13 Papillary carcinoma F/24 3×3 +++
14 Papillary carcinoma F/50 1×1+
15 Papillary carcinoma F/29 2×1.5 +++
16 Papillary carcinoma F/58 3.1×1.3 ++
17 Papillary carcinoma F/55 1.4×1.1 ++
18 Follicular carcinoma F/70 5×3.5 Skull +++ 
19 Follicular carcinoma F/36 6.5×3 LN ++ 
20 Follicular carcinoma F/44 4.5×4 LN +++ 
21 Follicular carcinoma F/56 3.8×2.8 ++
22 Follicular carcinoma M/53 3×3+ +
23 Follicular carcinoma M/19 6×5 +++
24 Follicular carcinoma F/62 3.5×3.5 +
25 Follicular carcinoma F/63 3×3+ +
26 Follicular carcinoma F/64 4×4 +++
Table 2. Clinicopathological features and FAK expression in thyroid cancer
+++, strong staining; ++, moderate staining; +, weak staining; -, no staining.712 S.J. Kim, J.W. Park, J.S. Yoon, et al.
and clinicopathological features (sex, tumor size, and meta-
stasis) was determined by the Spearman’s rank correlation. Chi-
square test was used for comparison of the FAK expression
in thyroid cancer and metastasis. A probability of p<0.05 was
considered statistically significant. All statistical analyses were
performed using SPSS for Windows version 11.0 (Chicago,
IL, U.S.A.).
RESULTS
Table 1 summarizes the results obtained for FAK immunos-
taining in thyroid tissues from 59 patients. FAK, when ex-
pressed, was found in the cytoplasm of follicular cells. FAK
staining was not seen in any of the 20 normal thyroid tissues
(Fig. 1A), and the 6 nodular hyperplasia specimens (Fig. 1B).
In contrast, FAK staining was observed in all of 17 papillary
carcinomas (Fig. 1E), 9 follicular carcinomas (Fig. 1F), 8 me-
dullary carcinomas (Fig. 1G) and 2 anaplastic carcinomas (Fig.
1H). In follicular adenoma, 8 cases were negative (Fig. 1C),
4 cases were weak, 2 cases were moderate, and 3 cases had
strong FAK positivity (Fig. 1D).
In papillary carcinoma, 7 cases had lymph node (LN) metas-
tasis, 1 case had soft tissue invasion, and 9 cases had neither.
In 7 cases with LN metastasis, 5 cases were strong, 1 case was
moderate, and 1 case was weak FAK staining. One case with
soft tissue invasion had strong FAK positivity. In 9 cases of
papillary carcinoma without LN metastasis or soft tissue inva-
sion, 4 cases were strong, 3 cases were moderate, and 2 cases
were weak FAK expression. In follicular carcinoma, 2 cases
had LN metastasis, which showed strong FAK expression in
one and moderate FAK expression in the other. One case had
distant metastasis to the skull and showed strong FAK expres-
sion. In 6 cases of follicular carcinoma without metastasis, 2
cases were strong, 3 cases were moderate, and 1 case had weak
FAK positivity (Table 2). The expression of FAK in thyroid
cancer was significantly increased. FAK expression was stron-
ger in thyroid cancer than in benign thyroid tumor (p=0.000),
Fig. 1. Immunohistochemical expression of FAK in thyroid nodules. (A) normal tissue, (B) nodular hyperplasia, (C) follicular adenoma that
shows negative immunostaining, (D) follicular adenoma that shows moderate immunostaining, (E) papillary carcinoma, (F) follicular carci-
noma, (G) medullary carcinoma, (H) anaplastic carcinoma (×400); All carcinoma tissues show the strong staining of FAK.
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but there were no differences in FAK expression between the
types of cancer. Sex, tumor size, and metastasis had no signifi-
cant correlation with FAK expression.
DISCUSSION
FAK plays an important role in cell proliferation. Zhao et
al. (20) demonstrated that overexpression of wild-type FAK
resulted in an accelerated G1 to S transition in Chinese ham-
ster ovary (CHO) cells, suggesting a role for FAK in the pro-
motion of cell proliferation. Several evidences have showed
that FAK promotes cell survival. Antibody or peptide block-
ing of FAK binding to integrins resulted in rapid cell death
of fibroblasts (21), and antisense oligonucleotides directed
toward FAK mRNA resulted in apoptosis of cancer cells (22).
Overexpression of FAK can rescue normal, suspended epithe-
lial cells from anoikis, a process by which adherent cells be-
come apoptotic after they are detached from their underlying
extracellular matrix as a result of the loss of integrin adhesion-
mediated FAK signaling (23, 24). FAK also promotes cell
migration. Ilic et al. (25) suggested that fibroblasts isolated
from FAK-knockout mice were shown to exhibit reduced cell
motility in culture, and Owen et al. (26) demonstrated that
FAK re-expression in FAK null cells restored cell migration.
Furthermore, ectopic expression of FRNK causes dephospho-
rylation of FAK at Tyr397 (27) and blocks FAK-mediated fib-
roblast migration (28), and overexpression of wild-type FAK
in CHO and African monkey kidney cell line COS cells result-
ed in increased cell migration (29, 30). Recent reports sug-
gest that p53 may be associated in function with the FAK.
Loss of cell adhesion deactivates FAK, causing anoikis through
the p53-mediated cell death pathway (23). Inhibition of FAK
induces apoptosis in normal cells and tumor cells in a p53
dependent manner (21, 31-33). In normal cells, FAK might
be a sensor of cell adhesion, limiting growth in anchorage-
dependent manner, whereas in transformed cells, overexpres-
sion of FAK may override this regulation and allow anchorage-
independent growth in the absence of cell adhesion. 
There are a lot of reports that FAK is overexpressed in var-
ious tumors, including tumors derived from the head and
neck, colon, breast, prostate, liver, cervix, and thyroid (10-
19). Owens et al. (14) assessed the level of FAK expression
in 30 human thyroid tissue samples from 27 patients that
included paired normal and malignant specimens by using
Western blot. The levels of FAK expression were directly
correlated with the most aggressive phenotype of thyroid
carcinomas. The highest levels of FAK were seen in follicular
carcinomas and tumors associated with distant metastatic
foci. In contrast, neoplastic thyroid tissues with limited inva-
sive potential, such as papillary carcinomas, follicular adeno-
mas, and other nonmalignant thyroid lesions, showed mini-
mal FAK expression. So they suggested that FAK might be
useful as a marker of invasive potential in differentiated thy-
roid cancer. These results were somewhat different from our
results. In our study, metastasis was not significantly corre-
lated with FAK expression. The expression of FAK may be
not related to invasion or metastasis, and clinical stage. In
ovarian (34) and prostate carcinoma (35), there also was no
association of FAK expression with the grade or stage of
tumor. Some reports argue that the invasiveness and metastatic
potential of human tumors is directly proportional to the
level of FAK expression (12, 22, 36). But Kahana et al. (37)
suggested that the mechanism by which FAK may be involv-
ed in tumorigenesis is not by overexpression but rather by
FAK constitutive activation. In our study, FAK was expressed
in all of the follicular and papillary carcinoma, and some of the
follicular adenoma, but was not expressed in normal tissue and
nodular hyperplasia. So, FAK overexpression may play a role
in the early event of de- velopment of thyroid carcinogenesis.
In this study, FAK was overexpressed in all of the medullary
thyroid carcinoma specimens. The RET gene is mutated in
more than 95% of patients with hereditary MTC (39) and in
up to 70% of DNA from sporadic tumors (40). RET signaling
has been shown to lead to phosphorylation of the adhesion-
dependent signaling molecules FAK, paxillin, and p130CAS
(41). Kim et al. (38) reported that FAK was constitutively
phosphorylated in MTC cells. But, they did not observe the
degree of FAK expression. Our study is the first report that
shows the overexpression of FAK in MTC. Therefore, consti-
tutive activation and overexpression of FAK may contribute
to MTC pathogenesis.
In summary, these results are the first immunohistochemi-
cal evidence that FAK expression is up-regulated in thyroid
cancers. This overexpression of FAK in tumors, combined with
the relative lack of expression in normal thyroid tissues, sug-
gests that FAK is a rational target for thyroid cancer therapeu-
tics. Further investigation of FAK as a clinical tumor marker
appears to be warranted.
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